CTLA4 and hypophysitis: The probability of hypophysitis in conjunction with immune checkpoint inhibitor use is as follows: combination therapy (nivolumab + ipilimumab), 6.4% and 3.2%; CTLA-4 inhibitors, 0.4%; and PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors, < 0.1% [73].